Use of Cerebrolysin for the Treatment of Posttraumatic Dementia

V.N. Mishchenko

Abstract


Recently, it has been found that a single moderate to severe traumatic brain injury (TBI) can subsequently lead to the development of posttraumatic dementia, more often by Alzheimer’s type, while multiple mild TBI (athletes, military) can result in the development of chronic traumatic encephalopathy. In case of traumatic brain injury as a risk factor for Alzheimer’s disease, β-amyloid and hyperphosphorylated tau-protein will be accumulated, whereas in the chronic traumatic encephalopathy — only hyperphosphorylated tau-protein. The chronic inflammation of immunoexcitotoxicity type underlies the long-term pathogenesis of both diseases. Between these diseases, there are differences in the clinical picture.
Cerebrolysin is a preparation that contains the fragments of the neurotrophic factors (CNTF, GDNF, IGF-1, IGF-2) and has neuroprotective and neuroregenerative effects in the brain structures. In patients with dementia, this drug reduces the accumulation of β-amyloid and hyperphosphorylated tau-protein, suppresses immunoexcitotoxicity. During treatment, this drug reduces the severity of cognitive and behavioral disorders, improves activities of daily living and global clinical functioning. Based on the current guidelines, it is appropriate to use Cerebrolysin for the treatment of traumatic brain injury as a risk factor for Alzheimer’s disease and chronic traumatic encephalopathy, with the expectation of high clinical results.


Keywords


posttraumatic dementia; Alzheimer’s disease; chronic traumatic encephalopathy; Cerebrolysin

References


Smith D.H., Johnson V.E., Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? / Nat. Rev. Neurol. — 2013. — V. 9, № 4. — P. 211-221.

Шевага В.Н. Ранние и отдаленные последствия черепно-мозговой травмы: медико-социальные аспекты и возможности нейропротекции / Здоров’я України. — 2009. — № 5/1. — С. 45.

Dementia resulting from traumatic brain injury: what is the pathology? / Shively S., Scher A.I., Perl D.P., Diaz-Arrastia R. // Arch. Neurol. — 2012. — V. 69, № 10. — P. 1245-1251.

Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on a partial replication / Fleminger S., Oliver D.L., Lovestone S. et al. // J. Neurol. Neurosurg. Psychiatry. — 2003. — V. 74, № 7. — P. 857-862.

Head injury and the risk of AD in the MIRAGE study / Guo Z., Cupples L.A., Kurz A. et al. // Neurology. — 2000. — V. 54, № 6. — P. 1316-1323.

Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias / Plassman B.L., Havlik R.J., Steffens D.C. et al. // Neurology. — 2000. — V. 55, № 8. — P. 1158-1166.

Institute of Medicine Committee on Gulf War and Health. Volume 7: Long-Term Consequences of Traumatic Brain Injury. — Washington, DC: National Academies Press, 2009. — P. 214.

Faden A.I., Loane D.J. Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation? // Neurotherapeutics. — 2014. — Nov 25 [Epub ahead of print].

Kahn H.A., Sempos C.T. Attributable Risk: Statistical Methods in Epidemiology. — New York: Oxford University Press, 1989. — P. 72-84.

Jordan B.D. The clinical spectrum of sport-related traumatic brain injury // Nat. Rev. Neurol. — 2013. — V. 9, № 4. — P. 222-230.

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury / Mitsis E.M., Riggio S., Kostakoglu L. et al. // Transl. Psychiatry. — 2014. — V. 16, № 4. — e441.

Johnson V.E., Stewart W., Smith D.H. Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans // Brain Pathol. — 2012. — V. 22, № 2. — P. 142-149.

Patterson Z.R., Holahan M.R. Understanding the neuroinflammatory response following concussion to develop treatment strategies // Front Cell Neurosci. — 2012. — V. 6, № 58. — doi: 10.3389/fncel.2012.00058.

Blaylock R.L., Maroon J. Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis // Surg. Neurol. Int. — 2011. — V. 2, № 107. — doi: 10.4103/2152-7806.83391.

Traumatic Brain Injury (TBI) Topic Sheet — Alzheimer's Association. — 2012. www.alz.org.

Bornstein N., Poon W.S. Accelerated recovery from acute brain injuries: clinical efficacy of neurotrophic treatment in stroke and traumatic brain injuries // Drugs Today (Barc). — 2012. — V. 48 (Suppl. A). — P. 43-61.

Cerebrolysin — product monograph // EVER Neuro Pharma. — 2010. — 84 p.

Álvarez X.A., Figueroa J., Muresanu D. Peptidergic Drugs for the Treatment of Traumatic Brain Injury // Future Neurology. — 2013. — V. 8, № 2. — P. 175-192.

Савустьяненко А.В. Эффекты Церебролизина и их значение // Международный неврологический журнал. — 2013. — Т. 2, № 56. — http://www.mif-ua.com/archive/article/35694.

The dentate gyrus neurogenesis: a therapeutic target for Alzheimer’s disease / Tatebayashi Y., Lee M.H., Li L. et al. // Acta Neuropathol. — 2003. — V. 105, № 3. — P. 225-232.

Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer’s disease / Rockenstein E., Mante M., Adame A. et al. // Acta Neuropathol. — 2007. — V. 113, № 3. — P. 265-275.

Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke / Zhang C., Chopp M., Cui Y. et al. // J. Neurosci. Res. — 2010. — V. 88, № 15. — P. 3275-3281.

Murdoch J.N., Copp A.J. The relationship between sonic Hedgehog signaling, cilia, and neural tube defects // Birth Defects Res. A. Clin. Mol. Teratol. — 2010. — V. 88, № 8. — P. 633-652.

Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke / Zhang L., Chopp M., Meier D.H. et al. // Stroke. — 2013. — V. 44, № 7. — P. 1965-1972.

Церебролизин: клиническое применение при травматическом повреждении головного мозга // EVER Neuro Pharma. — 2014. — 24 с.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease / Rockenstein E., Torrance M., Mante M. et al. // J. Neurosci. Res. — 2006. — V. 83, № 7. — P. 1252-1261.

Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin / Ubhi K., Rockenstein E., Doppler E. et al. // Acta Neuropathol. — 2009. — V. 117, № 6. — P. 699-712.

Cerebrolysin in mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials / Gauthier S., Proano J.V., Jia J. et al. // Journal of Dementia and Geriatric Cognitive Disorders. — 2014 (accepted for publication).

Cerebrolysin: treatment of cognitive impairment and dementia // EVER Neuro Pharma. — 2014. — 84 p.

Álvarez X.A., Fuentes P. Cerebrolysin in Alzheimer's disease // Drugs Today (Barc). — 2011. — V. 47, № 7. — P. 487-513.

Muresanu D.F., Rainer M., Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin // J. Neural Transm. Suppl. — 2002. — V. 62. — P. 277-285.

Allegri R.F., Guekht A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia // Drugs Today (Barc). — 2012. — V. 48, Suppl. A. — P. 25-41.

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease / Ruether, E., Husmann, R., Kinzler, E. et al. // Int. Clin. Psychopharmacol. — 2001. — V. 16, № 5. — P. 253-263.

Бачинская Н.Ю. Болезнь Альцгеймера // Доктор. — 2002. — № 5. — С. 27-30.

Полетаева К.Н., Холин В.А., Бачинская Н.Ю. Опыт применения Церебролизина у больных болезнью Альцгеймера и сосудистой деменцией // Международный неврологический журнал. — 2009. — Т. 6, № 28. — http://www.mif-ua.com/archive/article/11427

Castellani R.J. Chronic traumatic encephalopathy: a case series with review of current understanding // 2nd European Neurorehabilitation Congress in conjunction with the 3rd European Teaching Course on Neurorehabilitation. — Bucharest, 2013. June 26-28. — P. 27.

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure / Rockenstein E., Ubhi K., Trejo M. et al. // BMC Neuroscience. — 2014. — V. 15, № 90. — doi:10.1186/1471-2202-15-90.

Cerebrolysin attenuates astrocyte activation following repetitive mild traumatic brain injury: implications for chronic traumatic encephalopathy / Kang H.B., Kim G., Kim H. et al. // Journal of Life Science. — 2013. — V. 23, № 9. — P. 1096-1103.




DOI: https://doi.org/10.22141/2224-0713.4.74.2015.78227

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru